Neuroscience

• Policy / Pricing

Most patients “won’t see benefit” with Alzheimer’s drugs

pharminent April 16, 2026

• M&A / Deals

Parkinson’s charity partners Biognosys on biomarker project

pharminent April 15, 2026

• Regulatory

GSK again pulls application for leucovorin, touted by FDA as potential autism treatment

pharminent April 10, 2026

• M&A / Deals

Alzheimer’s biotech Korsana to go public via reverse merger

pharminent April 2, 2026

• M&A / Deals

Eli Lilly outlays $7.8bn to acquire sleep drug biotech Centessa

pharminent April 1, 2026

• M&A / Deals

Lilly beefs up neuroscience pipeline with $6.3B Centessa buyout

pharminent March 31, 2026

• M&A / Deals

Otsuka grows in neuroplastogens with $1.225bn Transcend buy

pharminent March 29, 2026

• M&A / Deals

Otsuka picks up PTSD drug with $700M Transcend buy

pharminent March 27, 2026

• Business
• Pipeline

How former Acorda CEO Ron Cohen landed at a Parkinson’s cell therapy startup

pharminent March 24, 2026